Physician profile
Brian Chen
NPI 1053792366
$7,870.21
in general payments reported to CMS, 2019-2025
33 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $795 · 2020: $2,375 · 2021: $1,705 · 2022: $1,396 · 2023: $421 · 2024: $730 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,436 · Education: $87.46 · Travel and Lodging: $76.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,435.86 |
| Education | $87.46 |
| Travel and Lodging | $76.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,219.74 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $935.97 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $510.51 | 2020-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals Lp | $452.91 | 2020-2025 | Farxiga |
| Astellas Pharma US INC | $397.67 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $372.40 | 2019-2024 | |
| Pfizer INC. | $360.88 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $336.67 | 2019-2024 | Xarelto |
| Atricure, INC. | $297.21 | 2022 | |
| Medtronic, INC. | $281.99 | 2021 | |
| Amgen INC. | $270.13 | 2021-2025 | Repatha, Repatha |
| Abiomed | $247.79 | 2019-2025 | Impella |
| Preventice Services, LLC | $175.63 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.80 | 2023-2024 | Jardiance |
| Irhythm Technologies, INC. | $135.67 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $109.92 | 2021 | |
| Edwards Lifesciences Corporation | $87.27 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Inspire Medical Systems, INC. | $76.03 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $67.09 | 2022-2025 | |
| Medtronic Vascular, INC. | $56.52 | 2019 | |
| Merck Sharp & Dohme LLC | $43.63 | 2022-2023 | Verquvo |
| W. L. Gore & Associates, INC. | $37.02 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $35.42 | 2021-2022 | |
| Philips North America LLC | $34.50 | 2024 | (5091) Amb Mon & Diag Und |
| Alnylam Pharmaceuticals INC. | $29.88 | 2023 | Amvuttra |
| Cleerly, INC. | $22.45 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Heartflow, INC. | $20.57 | 2022 | |
| Scpharmaceuticals INC. | $18.31 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $18.30 | 2024 | Arcalyst |
| Ardelyx, INC. | $16.02 | 2025 | Ibsrela |
| Angiodynamics, INC. | $14.83 | 2020 | |
| Baxter Healthcare | $14.45 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Regeneron Healthcare Solutions, INC. | $13.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.